The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

The ongoing Covid-19 pandemic propelled pharmaceutical institution Pfizer's net to a grounds $100 cardinal past year, astir $57 cardinal of which was driven by its vaccine and antiviral pill Paxlovid.

The vaccine accounted for $37.8 billion, up conscionable 3% from 2021, of Pfizer's full income arsenic request for the shots slowed. But income of its blockbuster antiviral attraction made up for that softening, surging to $18.9 cardinal successful 2022, the archetypal full-year that Paxlovid was connected the market.

Pfizer's combined income from its Covid vaccine and antiviral attraction generated much gross past twelvemonth than it had successful full income successful 2019, earlier the pandemic became a planetary situation that killed much than 6.8 cardinal radical and upended satellite markets. Those results won't beryllium repeated this year.

Pfizer told investors to expect gross to diminution successful 2023 by arsenic overmuch arsenic 33% to betwixt $67 cardinal and $71 cardinal arsenic the satellite emerges from the pandemic and request for its blockbuster Covid drugs slows.

Covid vaccines income are projected to plummet by 64% this twelvemonth to $13.5 cardinal from $37.8 cardinal successful 2022. Paxlovid income are expected to driblet 58% to $8 cardinal successful 2023 from $18.9 cardinal successful 2022.

Pfizer is besides forecasting that its full-year net per stock volition driblet by arsenic overmuch arsenic a 50%, from $3.25 to $3.45, from a grounds EPS of $6.58 successful 2022.

The company's fourth-quarter results were mostly successful enactment with analysts' expectations.

Pfizer CEO Albert Bourla past 4th laid retired a 2030 maturation program for the company that looks beyond the pandemic. Bourla said helium sees aboriginal gross maturation from RSV vaccines and medications for migraines and ulcerative colitis among different cause products.